Tolerability of ketorolac administered via continuous subcutaneous infusion for cancer pain: a preliminary report.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 8021534.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We evaluated the local and systemic tolerability of ketorolac administered through continuous subcutaneous infusion in ten cancer patients. The patients were monitored daily for the severity and duration of pain, and the development of other symptoms. The duration of injection site varied from 1 to more than 7 days. No patients complained of local discomfort or pain. Mild local bleeding at the site of drug injection was observed in seven cases. No increase in the intensity of symptoms was observed during the infusion of ketorolac.
Medical subject headings
- Analgesics
- Neoplasms
- Intractable Pain
- Tolmetin